The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy- camptothecin (SN-38) in combination with Gefitinib (Iressa™, ZD1839)

Biochemical Pharmacology

Volumn 68, Issue 1, 2004, Pages 135-144

  Azzariti, Amalia ^a   Xu, Jian Ming ^a,b   Porcelli, Letizia ^a   Paradiso, Angelo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Beijing 307 Hospital   (China)

Author keywords

3 4,5 dimethylthiazol 2 yl 2,5 diphenyltetrazoliumbromide; 5 fluorouracil; 5 FU; CI; combination index; dimethyl sulfoxide; DMSO; EDTA; EGFR; epidermal growth factor receptor; ethylenediaminetetraacetic acid; MTT; NB; neutralizing buffer; PBS

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IRINOTECAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG SYNERGISM; HT29 CELLS; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 2942560684     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.03.014     Document Type: Article

References (46)

1. Rothenberg M.L., Eckardt J.R., Kuhn J.G., Burris H.A. 3rd, Nelson J., Hilsenbeck S.G., et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. 14:1996;1128-1135
2. Rougier P., Bugat R., Douillard J.Y., Culine S., Suc E., Brunet P., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 15:1997;251-260
3. Paradiso A., Simone G., Petroni S., Leone B., Vallejo C., Lacava J., et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br. J. Cancer. 82:2000;560-567
4. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1990;1715-1720
5. Rivory L.P., Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol. Ther. 68:1995;269-296
6. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56:1987;881-914
7. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232
8. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8:2002;994-1003
9. Wakeling A.E., Barker A.J., Davies D.H., Brown D.S., Green L.R., Cartlidge S.A., et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 38:1996;67-73
10. Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., et al. ZD1839, an epidermal growth factor tyrosine kinase inibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. 38:1997;633. [Abstract 4251]
11. Hammond L.A., Figueroa J., Schwartzberg L., Ochoa L., Hidalgo M., Olivo N., et al. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;137a. [Abstract 544]
12. Albanell J., Rojo F., Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 28(Suppl 16):2001;56-66
13. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.-Y., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
14. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy and safety of Gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. J Am Med Assoc 2003;290(16):2149-58.
15. Sirotnak F.M., Zakowski M.F., Miller W.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892
16. Giaccone G., Johnson D.H., Manegold C., Scagliotti G.V., Rosell R., Wolf M., et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol. 13(Suppl 5):2002;2. [Abstract 40]
17. Johnson D.H., Herbst R., Giaccone G., Schiller J., Natale R.B., Miller V., et al. ZD1839 ("Iressa") in combination with paclitaxel, ZD1839 ("Iressa") in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13(Suppl 5):2002;127. [Absract 4680]
18. Cho C.D., Fisher G.A., Halsey J., Jambalos C.N., Advani R.H., Wakelee H., et al. A phase II study of Gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;265. [Abstract 1062]
19. Xu J.M., Azzariti A., Severino M., Lu B., Colucci G., Paradiso A. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem. Pharmacol. 66:2003;551-563
20. Xu J.M., Azzariti A., Colucci G., Paradiso A. Effect of Gefitinib ('Iressa', ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother. Pharmacol. 52(6):2003;442-448
21. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55
22. Chou TC, Rideout D, Chou J. Chemotherapeutic synergism, potentiation and antagonism. In: Dulbecco R, editor. Encyclopedia of human biology, vol. 2. New York: Academic Press; 1991. p. 371-9.
23. Chou J, Chou TC. Dose effect analysis with microcomputers. Cambridge: Biosoft; 1987.
24. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout D, editors. Synergism and antagonism in chemotherapy. New York: Academic Press; 1991. p. 61-102.
25. Codegoni A.M., Castagna S., Mangioni C., Scovassi A.I., Broggini M., D'Incalci M. DNA-Topoisomerase I activity and content in epithelial ovarian cancer. Ann. Oncol. 9:1998;313-319
26. Xu J.M., Azzariti A., Tommasi S., Lacalamita R., Colucci G., Johnston P.G., et al. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin. Colorectal Cancer. 2:2002;182-188
27. Oizumi S., Isobe H., Ogura S., Ishida T., Yamazaki K., Nishimura M., et al. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res. 22:2002;4029-4037
28. Gilmore A.P., Valentijn A.J., Wang P., Ranger A.M., Bundred N., O'Hare M.J., et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277:2002;27643-27650
29. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063
30. Williams K.J., Telfer B.A., Stratford I.J., Wedge S.R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer. 86:2002;1157-1161
31. Ciardiello F., Caputo R., Borriello G., Del Bufalo D., Biroccio A., Zupi G., et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer. 98:2002;463-469
32. Raben D., Helfrich B.A., Chan D., Johnson G., Bunn P.A. Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin. Oncol. 29(Suppl 4):2002;37-46
33. Magne N., Fischel J.L., Dubreuil A., Formento P., Marcie S., Lagrange J.L., et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of Gefitinib ("Iressa"). Br. J. Cancer. 86:2002;819-827
34. Tortora G., Caputo R., Damiano V., Fontanini G., Melisi D., Veneziani B.M., et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin. Cancer Res. 7:2001;4156-4163
35. Miller V.A., Johnson D., Heelan R.T., Pizzo B.A., Perez W.J., Bass A., et al. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;326a. [Abstract 1301]
36. Kindler H.L., Shulman K.L. Metastatic colorectal cancer. Curr. Treat. Options Oncol. 2:2001;459-471
37. Paradiso A, Xu JM, Azzariti A, Colucci G. Synergy between Gefitinib ('Iressa', ZD1839) and conventional cytotoxic agents (oxaliplatin or CPT-11) in colon cancer cell lines is dependent on the sequence of drug application. Proc Am Assoc Cancer Res 2003;44:867 [Abstract 3791].
38. Kometani T, Hirata A, Miyagawa M, Kuwano M, Ono M. Drug sensitivity of Gefitinib ('Iressa') correlates with Ras-Map kinase and PI3-Akt kinase pathways in non-small cell lung cancer cells. Proc Am Assoc Cancer Res 2003;44:1074 [Abstract 4681].
39. Shimoyama T, Koizum F, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor Gefitinib ('Iressa') and the topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Proc Am Assoc Cancer Res 2003;44:866 [Abstract 3786].
40. Sugiyama K, Yamashita K, Nishio K, Akinga S, Kanazawa J. Synergistic combined effect of vinorelbine and Gefitinib (Iressa) in NSCLC cell lines which overexpress the phosphorylated EGFR and EebB2. Proc Am Assoc Cancer Res 2003;44:625 [Abstract 2737].
41. Miyazaki M, Tamura K, Kurata T, Uejima H, Nogami T, Yonesaka K, et al. Synergistic antitumor activity of Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with vinorelbine in human lung cancer xenografts. Proc Am Assoc Cancer Res 2003;44:851 [Abstract 3720].
42. Lee S., Lee H.S., Baek M., Lee D.Y., Bang Y.J., Cho H.N., et al. ERK1/2 signaling is involved in camptothecin-induced cell death. Mol. Cells. 14:2002;348-354
43. Takeda Y., Nishio K., Niitani H., Sanijo N. Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line. Int. J. Cancer. 57:1994;229-239
44. Meyers M.B., Merluzzi V.J., Spengler B.A., Biedler J.L. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc. Natl. Acad. Sci. U.S.A. 83:1986;5521-5525
45. Kurata T., Tamura K., Kaneda H., Nogami T., Uejima H., Asai G., et al. Effect of re-treatment with gefinitib (iressa, ZD1839) after acquisition of resistance. Ann. Oncol. 15:2004;173-177
46. Nakamura Y, Oka M, Shiozawa K, Nakatomi K, Yoshikawa M, Kawabata S, et al. Gefitinib ('Iressa', ZD1839) inhibits topotecan-efflux in small-cell lung cancer cells overexpressing breast cancer resistance protein (BCRP/ABCG2). Proc Am Assoc Cancer Res 2003;44:1073 [Abstract 4679].